$RNAC
Cartesian Therapeutics, Inc.

2020 Q2 Form 10-Q Financial Statement

#000145368720000096 Filed on August 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $0.00 $13.00K
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.640M $4.110M
YoY Change 37.23% -5.73%
% of Gross Profit
Research & Development $10.73M $12.13M
YoY Change -11.57% -15.78%
% of Gross Profit
Depreciation & Amortization $200.0K $200.0K
YoY Change 0.0% -50.0%
% of Gross Profit
Operating Expenses $16.37M $16.25M
YoY Change 0.73% -13.43%
Operating Profit -$16.37M -$16.24M
YoY Change 0.81% -13.5%
Interest Expense $205.0K $400.0K
YoY Change -48.75% 9.59%
% of Operating Profit
Other Income/Expense, Net $59.00K $5.000K
YoY Change 1080.0% -37.5%
Pretax Income -$24.08M -$16.39M
YoY Change 46.92% -12.82%
Income Tax
% Of Pretax Income
Net Earnings -$24.08M -$16.39M
YoY Change 46.89% -12.78%
Net Earnings / Revenue -126107.69%
Basic Earnings Per Share -$0.25
Diluted Earnings Per Share -$0.25 -$365.4K
COMMON SHARES
Basic Shares Outstanding 96.79M shares 44.79M shares
Diluted Shares Outstanding 96.79M shares

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $59.70M $41.70M
YoY Change 43.17% -37.01%
Cash & Equivalents $59.73M $30.20M
Short-Term Investments $11.50M
Other Short-Term Assets $1.300M $2.800M
YoY Change -53.57% 7.69%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $61.05M $44.45M
YoY Change 37.35% -35.43%
LONG-TERM ASSETS
Property, Plant & Equipment $1.301M $1.620M
YoY Change -19.69% -24.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.400M $0.00
YoY Change -100.0%
Total Long-Term Assets $14.15M $2.498M
YoY Change 466.61% -45.72%
TOTAL ASSETS
Total Short-Term Assets $61.05M $44.45M
Total Long-Term Assets $14.15M $2.498M
Total Assets $75.21M $46.95M
YoY Change 60.19% -36.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.242M $2.463M
YoY Change -49.57% 37.67%
Accrued Expenses $9.308M $5.789M
YoY Change 60.79% -43.16%
Deferred Revenue $1.928M $1.023M
YoY Change 88.47% -46.66%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $8.400M $21.50M
YoY Change -60.93%
Total Short-Term Liabilities $22.51M $31.91M
YoY Change -29.45% 129.7%
LONG-TERM LIABILITIES
Long-Term Debt $6.400M $0.00
YoY Change -100.0%
Other Long-Term Liabilities $59.30M $0.00
YoY Change -100.0%
Total Long-Term Liabilities $65.70M $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.51M $31.91M
Total Long-Term Liabilities $65.70M $0.00
Total Liabilities $88.26M $46.89M
YoY Change 88.22% -4.64%
SHAREHOLDERS EQUITY
Retained Earnings -$379.5M -$308.9M
YoY Change 22.86% 24.96%
Common Stock $10.00K $5.000K
YoY Change 100.0% 66.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$13.05M $56.00K
YoY Change
Total Liabilities & Shareholders Equity $75.21M $46.95M
YoY Change 60.19% -36.07%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$24.08M -$16.39M
YoY Change 46.89% -12.78%
Depreciation, Depletion And Amortization $200.0K $200.0K
YoY Change 0.0% -50.0%
Cash From Operating Activities -$11.81M -$7.200M
YoY Change 64.03% -57.57%
INVESTING ACTIVITIES
Capital Expenditures -$190.0K -$10.00K
YoY Change 1800.0% -96.3%
Acquisitions
YoY Change
Other Investing Activities $50.00K $4.850M
YoY Change -98.97% -74.41%
Cash From Investing Activities -$150.0K $4.850M
YoY Change -103.09% -74.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -960.0K 370.0K
YoY Change -359.46% 19.35%
NET CHANGE
Cash From Operating Activities -11.81M -7.200M
Cash From Investing Activities -150.0K 4.850M
Cash From Financing Activities -960.0K 370.0K
Net Change In Cash -12.92M -1.980M
YoY Change 552.53% -198.02%
FREE CASH FLOW
Cash From Operating Activities -$11.81M -$7.200M
Capital Expenditures -$190.0K -$10.00K
Free Cash Flow -$11.62M -$7.190M
YoY Change 61.61% -56.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37798
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Entity Central Index Key
EntityCentralIndexKey
0001453687
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86325547 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
100847810 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86325547 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100847810 shares
CY2019Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000 USD
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000 USD
us-gaap Depreciation
Depreciation
400000 USD
CY2020Q2 us-gaap Depreciation
Depreciation
200000 USD
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
dei Entity Registrant Name
EntityRegistrantName
Selecta Biosciences, Inc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1622110
dei Entity Address Address Line1
EntityAddressAddressLine1
65 Grove Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
923-1400
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
SELB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-29000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 USD
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2020Q2 us-gaap Assets
Assets
75206000 USD
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1928000 USD
CY2019Q4 us-gaap Assets
Assets
99569000 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1242000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
500000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9308000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13492000 USD
CY2020Q2 us-gaap Loans Payable Current
LoansPayableCurrent
8384000 USD
CY2019Q4 us-gaap Loans Payable Current
LoansPayableCurrent
18905000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1648000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1674000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
22510000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
34943000 USD
CY2020Q2 us-gaap Long Term Loans Payable
LongTermLoansPayable
6449000 USD
CY2019Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
0 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10120000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2020Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
16412000 USD
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Liabilities
Liabilities
91172000 USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
10000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
9000 USD
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
370944000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
348664000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-379454000 USD
us-gaap Investment Income Net
InvestmentIncomeNet
523000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-335753000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4523000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-13052000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
8397000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75206000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
99569000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
23000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10730000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12134000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25454000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19487000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5637000 USD
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4114000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9735000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8627000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
16367000 USD
CY2020Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-42000 USD
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
16248000 USD
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
us-gaap Operating Expenses
OperatingExpenses
35189000 USD
us-gaap Operating Expenses
OperatingExpenses
28114000 USD
CY2019Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-10000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16367000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16235000 USD
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
107143410 shares
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59730000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
89893000 USD
CY2020Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
278000 USD
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
dei Document Type
DocumentType
10-Q
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
279000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5000000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1044000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1495000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
61052000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
96667000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1301000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1222000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11474000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
301000 USD
CY2020Q2 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
1379000 USD
CY2019Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
1379000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-35189000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-28091000 USD
CY2020Q2 us-gaap Investment Income Net
InvestmentIncomeNet
13000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
372000 USD
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
14680000 USD
CY2020Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
32767000 USD
CY2019Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
41549000 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
40000 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-40000 USD
CY2020Q2 us-gaap Liabilities
Liabilities
88258000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
205000 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
400000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
58000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-64000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-24081000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4552000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
29000 USD
us-gaap Interest Expense
InterestExpense
478000 USD
us-gaap Interest Expense
InterestExpense
796000 USD
CY2020Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
7539000 USD
CY2019Q2 us-gaap Investment Income Net
InvestmentIncomeNet
246000 USD
us-gaap Investment Income Net
InvestmentIncomeNet
253000 USD
CY2019Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
8385000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
59000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-16394000 USD
us-gaap Net Income Loss
NetIncomeLoss
-43701000 USD
us-gaap Net Income Loss
NetIncomeLoss
-28468000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
31000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
7000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24050000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16386000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43730000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28436000 USD
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
96785915 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44855083 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
95754714 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41668902 shares
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
8397000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
114000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1141000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-147000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1409000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-60000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-19620000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-8763000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
98000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
967000 USD
CY2020Q2 selb Stock Issued During Period Value Pre Funded Warrants Exercised
StockIssuedDuringPeriodValuePreFundedWarrantsExercised
1000 USD
CY2020Q2 selb Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
17214000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1481000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
31000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-24081000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-13052000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-5418000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
20000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
145000 USD
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30942000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1180000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
22000 USD
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-12074000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
14819000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
372000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1251000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
7000 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-16394000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
56000 USD
us-gaap Net Income Loss
NetIncomeLoss
-43701000 USD
us-gaap Net Income Loss
NetIncomeLoss
-28468000 USD
us-gaap Depreciation
Depreciation
356000 USD
us-gaap Depreciation
Depreciation
355000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
131000 USD
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
602000 USD
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
723000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
35000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-76000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2890000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2431000 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
173000 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
267000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
8385000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5000000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-451000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2189000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
735000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1363000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2000000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-11000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-362000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6231000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23506000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27437000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
0 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
4850000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
18188000 USD
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
0 USD
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
1992000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
334000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
45000 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
4381000 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
145000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
114000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
77000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-289000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11274000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
4200000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
30942000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-147000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
101000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
20000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-6327000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31479000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-42000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
29000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-30164000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7203000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
91551000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37682000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61387000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30479000 USD
us-gaap Interest Paid Net
InterestPaidNet
387000 USD
us-gaap Interest Paid Net
InterestPaidNet
634000 USD
selb Noncash Or Part Noncash Warrant Exercises
NoncashOrPartNoncashWarrantExercises
17089000 USD
selb Noncash Or Part Noncash Warrant Exercises
NoncashOrPartNoncashWarrantExercises
0 USD
selb Noncash Or Part Noncash Reclassification Of Warrant Liability To Equity
NoncashOrPartNoncashReclassificationOfWarrantLiabilityToEquity
77000 USD
selb Noncash Or Part Noncash Reclassification Of Warrant Liability To Equity
NoncashOrPartNoncashReclassificationOfWarrantLiabilityToEquity
0 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
111000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
selb Equity Offering Costs In Accrued Liabilities
EquityOfferingCostsInAccruedLiabilities
29000 USD
selb Equity Offering Costs In Accrued Liabilities
EquityOfferingCostsInAccruedLiabilities
14000 USD
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0 USD
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
3000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61400000 USD
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1700000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-379500000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-335800000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4781000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1301000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s management considers many factors in selecting appropriate financial accounting policies and controls, and bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. In preparing these consolidated financial statements, management used significant estimates in the following areas, among others: revenue recognition, accounting for stock-based compensation, the valuation of its warrant liabilities and estimating accrued research and development expenses. The Company assesses the above estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span></div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59730000 USD
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30200000 USD
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
278000 USD
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
279000 USD
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1379000 USD
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
0 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61387000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30479000 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentrations of Credit Risk and Off‑Balance Sheet Risk</span></div>Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, short-term deposits and investments, and accounts receivable. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. Management believes that the financial institutions that hold the Company’s deposits are financially creditworthy and, accordingly, minimal risk exists with respect to those balances. Generally, these deposits may be redeemed upon demand and therefore bear minimal interest rate risk. As an integral part of operating its Russian subsidiary, the Company also maintains cash in Russian bank accounts in denominations of both Russian rubles and U.S. dollars.
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1222000 USD
CY2019Q2 us-gaap Depreciation
Depreciation
200000 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24081000 USD
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16394000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-43701000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28468000 USD
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
96785915 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44855083 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
95754714 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41668902 shares
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22474088 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5008082 shares
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5373000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6003000 USD
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4072000 USD
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
613000 USD
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
341000 USD
us-gaap Depreciation
Depreciation
400000 USD
selb Plant Property And Equipment Accelerated Depreciation
PlantPropertyAndEquipmentAcceleratedDepreciation
100000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
373000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
414000 USD
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2112000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2235000 USD
CY2020Q2 selb Accrued Collaborationand Licensing
AccruedCollaborationandLicensing
1350000 USD
CY2019Q4 selb Accrued Collaborationand Licensing
AccruedCollaborationandLicensing
1050000 USD
CY2020Q2 selb Accrued Patent Fees Current
AccruedPatentFeesCurrent
492000 USD
CY2019Q4 selb Accrued Patent Fees Current
AccruedPatentFeesCurrent
487000 USD
CY2020Q2 selb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
4247000 USD
CY2019Q4 selb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
4379000 USD
CY2020Q2 selb Accrued Audit Fees Current
AccruedAuditFeesCurrent
763000 USD
CY2019Q4 selb Accrued Audit Fees Current
AccruedAuditFeesCurrent
468000 USD
CY2020Q2 us-gaap Interest Payable Current
InterestPayableCurrent
44000 USD
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
82000 USD
CY2020Q2 us-gaap Accumulated Amortization Of Current Deferred Finance Costs
AccumulatedAmortizationOfCurrentDeferredFinanceCosts
0 USD
CY2019Q4 us-gaap Accumulated Amortization Of Current Deferred Finance Costs
AccumulatedAmortizationOfCurrentDeferredFinanceCosts
4381000 USD
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
300000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
410000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9308000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13492000 USD
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.089
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
800000 USD
CY2019Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
1400000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
1100000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
1085000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
372000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10120000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
682000 USD
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
174000 USD
CY2019Q2 us-gaap Variable Lease Cost
VariableLeaseCost
211000 USD
CY2020Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
3000 USD
CY2019Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
3000 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
5000 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
11000 USD
CY2020Q2 us-gaap Lease Cost
LeaseCost
790000 USD
CY2019Q2 us-gaap Lease Cost
LeaseCost
555000 USD
us-gaap Lease Cost
LeaseCost
1463000 USD
us-gaap Lease Cost
LeaseCost
1107000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1698000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
375000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1812000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
0 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1866000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
0 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1922000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1980000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0 USD
CY2020Q2 selb Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
6985000 USD
CY2019Q4 selb Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
0 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
16263000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
375000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4495000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3000 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
11768000 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
372000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1648000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y10M24D
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
11768000 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
372000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
825000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
735000 USD
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y3M18D
CY2020Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
27757227 shares
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
40169185 shares
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.089
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.100
selb Debt Instrument Event Of Default Minimum Assets Trigger
DebtInstrumentEventOfDefaultMinimumAssetsTrigger
300000 USD
selb Debt Instrument Event Of Default Minimum Amount In Excess Of Indebtedness Trigger
DebtInstrumentEventOfDefaultMinimumAmountInExcessOfIndebtednessTrigger
300000 USD
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
31426248000 shares
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.12
selb Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
16585148000 shares
us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
0.73
CY2020Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
14841100000 shares
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.56
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
100847810 shares
CY2020Q2 selb Votes Per Shareof Common Stock
VotesPerShareofCommonStock
1 vote
us-gaap Dividends Common Stock
DividendsCommonStock
0 USD
CY2020Q2 selb Contractwith Customer Liability Deferred Revenue
ContractwithCustomerLiabilityDeferredRevenue
18340000 USD
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
16354000 USD
selb Contractwith Customer Liability Increase From Cash Receipts
ContractwithCustomerLiabilityIncreaseFromCashReceipts
2000000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
14000 USD
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
18340000 USD
CY2020Q2 selb Share Based Goods And Non Employee Services Transaction Compensation Not Yet Recognized Stock Options
ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions
0 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1481000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1251000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2890000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2431000 USD
CY2016Q4 selb License And Option Agreement Number Of Additional Targets For Which Other Party May Exercise Options For Additional Licenses
LicenseAndOptionAgreementNumberOfAdditionalTargetsForWhichOtherPartyMayExerciseOptionsForAdditionalLicenses
4 target
CY2020Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
18300000 USD
CY2019Q4 selb Contractwith Customer Liability Deferred Revenue
ContractwithCustomerLiabilityDeferredRevenue
16354000 USD
selb Contractwith Customer Liability Deferred Revenue Increase From Cash Receipts
ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts
2000000 USD
selb Contractwith Customer Liability Deferred Revenue Revenue Recognized
ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized
14000 USD
CY2020Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
selb Defined Contribution Plan Employers Matching Contribution Vesting Period
DefinedContributionPlanEmployersMatchingContributionVestingPeriod
P4Y
CY2020Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000 USD
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000 USD

Files In Submission

Name View Source Status
0001453687-20-000096-index-headers.html Edgar Link pending
0001453687-20-000096-index.html Edgar Link pending
0001453687-20-000096.txt Edgar Link pending
0001453687-20-000096-xbrl.zip Edgar Link pending
exhibit101mitfifthamen.htm Edgar Link pending
exhibit102sobilicensea.htm Edgar Link pending
exhibit103sobistockpur.htm Edgar Link pending
exhibit31106302020.htm Edgar Link pending
exhibit31206302020.htm Edgar Link pending
exhibit32106302020.htm Edgar Link pending
exhibit32206302020.htm Edgar Link pending
exhibit41sobiregistrat.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
selb-20200630.xsd Edgar Link pending
selb-20200630_cal.xml Edgar Link unprocessable
selb-20200630_def.xml Edgar Link unprocessable
selb-20200630_lab.xml Edgar Link unprocessable
selb-20200630_pre.xml Edgar Link unprocessable
selectabiosciences10-q.htm Edgar Link pending
selectabiosciences10-q_htm.xml Edgar Link completed
Show.js Edgar Link pending